<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4277">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643548</url>
  </required_header>
  <id_info>
    <org_study_id>NeuroCovid-RNI 2020 GODET</org_study_id>
    <nct_id>NCT04643548</nct_id>
  </id_info>
  <brief_title>WHO Covid 19 - Neurological Abnormalities in SARS-CoV-2 ICU Patients</brief_title>
  <acronym>NeuroCovid</acronym>
  <official_title>Neurological Abnormalities in SARS-CoV-2 ICU Patients. A Prospective Study. NeuroCOVID Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SARS-CoV-2 epidemic is leading to a large number of patients in intensive care units due&#xD;
      to severe hypoxemic pneumonia. After an acute phase that may require controlled mechanical&#xD;
      ventilation and deep sedation, removal of sedation often reveals a pathological awakening in&#xD;
      the vast majority of patients. This encephalopathy state remains, to date and to our&#xD;
      knowledge, unexplained. Clinical features do not appear to fully correlate with regular&#xD;
      delirium. This encephalopathy might be explained by deep and prolonged hypoxemia, a wide use&#xD;
      of sedation drugs, systemic inflammation or the hostile ICU environment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to investigate neurological abnormalities associated with SARS-CoV-2&#xD;
      infection. Complete daily neurological examinations will be routinely conducted in intensive&#xD;
      care unit patients. Specific biological analyses will also be performed in these patients by&#xD;
      collecting additional blood samples from an arterial or central catheter, every 2 days. These&#xD;
      clinical and biological examinations will be continued throughout patient's stay in the&#xD;
      intensive care unit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Anticipated">August 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dosage of biomarkers typically explored in intensive care unit delirium</measure>
    <time_frame>Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 days</time_frame>
    <description>Plasminogen activator inhibitor-1 (PAI-1), E-selectin and angiopoietin-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosage of neuronal injury markers</measure>
    <time_frame>Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 days</time_frame>
    <description>S100 β, Neuron Specific Enolase (NSE), GFAP, UCHL1, NFL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delirium assessment</measure>
    <time_frame>Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days</time_frame>
    <description>CAM-ICU (Confusion Assessment Method - Intensive Care Unit) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium assessment</measure>
    <time_frame>Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days</time_frame>
    <description>ICDSC (Intensive Care Delirium Screening Checklist) scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coma assessment</measure>
    <time_frame>Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days</time_frame>
    <description>CRS-R (Coma Recovery Scale-Revised)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupils characteristics</measure>
    <time_frame>Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days</time_frame>
    <description>Clinical observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupils characteristics</measure>
    <time_frame>Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days</time_frame>
    <description>Pupilometer assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological abnormalities</measure>
    <time_frame>Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days</time_frame>
    <description>Electroencephalogram : epileptic activity (spikes, spike-waves) or encephalopathy activity (triphasic waves))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological abnormalities</measure>
    <time_frame>Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days</time_frame>
    <description>CT-scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological abnormalities</measure>
    <time_frame>Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days</time_frame>
    <description>MRI</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>Intensive Care Unit Patient</condition>
  <condition>Neurological Abnormality</condition>
  <condition>Delirium</condition>
  <condition>Encephalopathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients hospitalized in Intensive Care Unit and infected bye SARS-CoV-2&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  COVID-19 positive patient (positive RT PCR, nasopharyngeal or tracheal)&#xD;
&#xD;
          -  Patient admitted in an intensive care unit of the department of Anesthesia, Critical&#xD;
             Care and Perioperative of Clermont-Ferrand University Hospital&#xD;
&#xD;
          -  Patient with an arterial or central catheter to perform blood samples collection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient or family member's refusal to participate&#xD;
&#xD;
          -  Neuropsychiatric history that may interfere with neurological evaluations in the&#xD;
             intensive care unit&#xD;
&#xD;
          -  Patient not affiliated with French social security insurance&#xD;
&#xD;
          -  Patient under legal guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Lise Laclautre</last_name>
    <phone>+33 4 754 963</phone>
    <email>llaclautre_perrier@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Godet</last_name>
      <email>tgodet@chu-clermontferrand.fr</email>
    </contact>
    <contact_backup>
      <last_name>Benjamin Rieu</last_name>
      <email>brieu@chu-clermontferrand.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>November 28, 2020</last_update_submitted>
  <last_update_submitted_qc>November 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2 infection</keyword>
  <keyword>Intensive care unit patient</keyword>
  <keyword>Neurological abnormalities</keyword>
  <keyword>Delirium</keyword>
  <keyword>Encephalopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Nervous System Malformations</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

